Literature DB >> 15890767

C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion.

O Wazni1, D O Martin, N F Marrouche, M Shaaraoui, M K Chung, S Almahameed, R A Schweikert, W I Saliba, A Natale.   

Abstract

BACKGROUND: To test the hypothesis that a high C reactive protein (CRP) concentration would predict recurrence of atrial fibrillation (AF) after cardioversion in patients taking antiarrhythmic drugs.
METHODS: 111 patients who underwent direct current cardioversion for symptomatic AF were enrolled. Blood was drawn for CRP determination before cardioversion on the same day. All patients were taking antiarrhythmic drugs before and after electrical cardioversion.
RESULTS: After a mean follow up of 76 days, 75 patients had recurrence of AF. In univariate analysis, the median CRP concentration was significantly higher in patients with AF recurrence (3.95 mg/l v 1.81 mg/l, p = 0.002). Among the 55 patients with CRP in the upper 50th centile, 44 (80%) experienced recurrence of AF over a total follow up of 8.98 patient years, whereas among the 56 patients with CRP in the lower 50th centile, 31 (55%) experienced recurrence of AF over a total follow up of 14.3 patient years (p < 0.001). The adjusted hazard ratio comparing the upper 50th centile of CRP with the lower 50th centile of CRP was 2.0 (95% confidence interval 1.2 to 3.2, p = 0.007).
CONCLUSIONS: CRP is independently associated with recurrence of AF after electrical cardioversion among patients taking antiarrhythmic drugs. These results suggest that inflammation may have a role in the pathogenesis of AF resistant to antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890767      PMCID: PMC1769138          DOI: 10.1136/hrt.2004.038661

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  26 in total

Review 1.  Pathophysiology and prevention of atrial fibrillation.

Authors:  M A Allessie; P A Boyden; A J Camm; A G Kléber; M J Lab; M J Legato; M R Rosen; P J Schwartz; P M Spooner; D R Van Wagoner ; A L Waldo
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

Review 2.  Atrial fibrillation.

Authors:  R H Falk
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

3.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  Statins promote potent systemic antioxidant effects through specific inflammatory pathways.

Authors:  Mehdi H Shishehbor; Marie-Luise Brennan; Ronnier J Aviles; Xiaoming Fu; Marc S Penn; Dennis L Sprecher; Stanley L Hazen
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

5.  Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release.

Authors:  D J Brull; J Sanders; A Rumley; G D Lowe; S E Humphries; H E Montgomery
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

6.  C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation.

Authors:  M K Chung; D O Martin; D Sprecher; O Wazni; A Kanderian; C A Carnes; J A Bauer; P J Tchou; M J Niebauer; A Natale; D R Van Wagoner
Journal:  Circulation       Date:  2001-12-11       Impact factor: 29.690

7.  Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.

Authors:  B López; R Querejeta; N Varo; A González; M Larman; J L Martínez Ubago; J Díez
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

Review 8.  Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation.

Authors:  I C Van Gelder; A E Tuinenburg; B S Schoonderwoerd; R G Tieleman; H J Crijns
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

9.  Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan.

Authors:  M A Fortuño; S Ravassa; J C Etayo; J Díez
Journal:  Hypertension       Date:  1998-08       Impact factor: 10.190

10.  Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

Authors:  Antonio H Madrid; Manuel G Bueno; Jose M G Rebollo; Irene Marín; Gonzalo Peña; Enrique Bernal; Aníbal Rodriguez; Lucas Cano; José M Cano; Pedro Cabeza; Concepción Moro
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

View more
  18 in total

1.  NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation.

Authors:  Jinqi Fan; Hua Cao; Li Su; Zhiyu Ling; Zengzhang Liu; Xianbin Lan; Yanping Xu; Weijie Chen; Yuehui Yin
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

Review 2.  [Atrial fibrillation].

Authors:  M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

3.  Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

Authors:  Ibrahim R Hanna; Brent Heeke; Heather Bush; Lynne Brosius; Diane King-Hageman; Samuel C Dudley; John F Beshai; Jonathan J Langberg
Journal:  Heart Rhythm       Date:  2006-05-09       Impact factor: 6.343

4.  C-Reactive Protein and The Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Venkata M Alla; Senthil Thambidorai; Kishlay Anand; Aryan N Mooss; Richard Baltaro; Syed M Mohiuddin
Journal:  J Atr Fibrillation       Date:  2010-01-01

5.  Atrial fibrillation and inflammation.

Authors:  Mehmet Ozaydin
Journal:  World J Cardiol       Date:  2010-08-26

6.  High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion.

Authors:  Enrico Vizzardi; Savina Nodari; Gregoriana Zanini; Alessandra Manerba; Silvia Frattini; Alberto Madureri; Riccardo Raddino; Livio Dei Cas
Journal:  Intern Emerg Med       Date:  2009-03-14       Impact factor: 3.397

Review 7.  The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy.

Authors:  Yehuda Edo Paz; Sabahat Bokhari
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-30       Impact factor: 2.357

Review 8.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

Review 9.  Clinical use of and future perspectives on antiarrhythmic drugs.

Authors:  Juan Carlos Estrada; Dawood Darbar
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

10.  Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion.

Authors:  Rupak Mukherjee; Joseph G Akar; J Marcus Wharton; Deborah K Adams; Catherine D McClure; Robert E Stroud; Allison D Rice; Stacia M DeSantis; Francis G Spinale; Michael R Gold
Journal:  J Cardiovasc Transl Res       Date:  2013-05-31       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.